Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials.
Anegondi N, Steffen V, Sadda SR, Schmitz-Valckenberg S, Tufail A, Csaky K, Lad EM, Kaiser PK, Ferrara D, Chakravarthy U. Anegondi N, et al. Among authors: kaiser pk. Ophthalmology. 2024 Nov 23:S0161-6420(24)00742-5. doi: 10.1016/j.ophtha.2024.11.017. Online ahead of print. Ophthalmology. 2024. PMID: 39581330 Free article.
The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A, Nanji K, Tai F, Phillips M, Zeraatkar D, Garg SJ, Sadda SR, Kaiser PK, Guymer RH, Sivaprasad S, Wykoff CC, Chaudhary V. Garg A, et al. Among authors: kaiser pk. Surv Ophthalmol. 2024 May-Jun;69(3):349-361. doi: 10.1016/j.survophthal.2023.11.008. Epub 2023 Nov 24. Surv Ophthalmol. 2024. PMID: 38008405
Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM; INTREPID Study Group. Jackson TL, et al. Among authors: kaiser pk. Ophthalmology. 2013 Sep;120(9):1893-900. doi: 10.1016/j.ophtha.2013.02.016. Epub 2013 Mar 13. Ophthalmology. 2013. PMID: 23490327 Clinical Trial.
International Classification System for Ocular Complications of Anti-VEGF Agents in Clinical Trials.
Popovic MM, Balas M, Sadda SR, Sarraf D, Huang R, Bakri SJ, Berrocal A, Chang A, Gemmy Cheung CM, Garg S, Hillier RJ, Holz FG, Johnson MW, Kaiser PK, Kertes PJ, Lai TYY, Noble J, Park SS, Paulus YM, Querques G, Rachitskaya A, Ruamviboonsuk P, Saidkasimova S, Sandinha MT, Steel DH, Terasaki H, Weng CY, Williams BK Jr, Wu L, Muni RH. Popovic MM, et al. Among authors: kaiser pk. Ophthalmology. 2024 Dec;131(12):1457-1467. doi: 10.1016/j.ophtha.2024.06.011. Epub 2024 Jun 13. Ophthalmology. 2024. PMID: 38878904 Free article.
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.
Ehlers JP, Hu A, Boyer D, Cousins SW, Waheed NK, Rosenfeld PJ, Brown D, Kaiser PK, Abbruscato A, Gao G, Heier J; ReCLAIM-2 (SPIAM-202) Study Investigators. Ehlers JP, et al. Among authors: kaiser pk. Ophthalmol Sci. 2024 Oct 9;5(1):100628. doi: 10.1016/j.xops.2024.100628. eCollection 2025 Jan-Feb. Ophthalmol Sci. 2024. PMID: 39605874 Free PMC article.
315 results